在早期乳腺癌中确定基因表达预测新辅助内分泌疗法的反应
Kaori Hidaka1,2, Lisa Goto-Yamaguchi2, Aiko Sueta3
1Department of Thoracic Surgery and Breast Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Breast cancer research and treatment
|April 9, 2025
概括
研究人员确定CXCL9和NPY1R是预测雌激素受体阳性乳腺癌患者内分泌治疗反应的潜在生物标志物. 这些基因可以通过识别那些可能从额外疗法中受益的人来帮助个性化治疗.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 药物基因组学 药物基因组学
背景情况:
- 雌激素受体 (ER) 阳性乳腺癌是最常见的亚型,用内分泌疗法治疗.
- 尽管接受治疗,但复发风险仍然存在,这凸显了对预测生物标志物的需求.
- 在新辅助性内分泌疗法 (sNAET) 后的低Ki67水平与更好的结果相关.
研究的目的:
- 在ER阳性乳腺癌中通过sNAET识别与细胞循环抑制相关的基因.
- 为了找到内分泌治疗反应的预测生物标志物.
主要方法:
- 根据sNAET之前和之后的Ki67水平,分析了绝经后患者的97个瘤样本.
- 利用RNA测序和RT-qPCR来评估基因表达.
- 将患者分为两层,分为高高 (H-H) 和高低 (H-L) Ki67组.
主要成果:
- 在H-H组中,CXCL9和ABCA12的调节升高,表明内分泌治疗反应不佳.
- 在H-L组中,NPY1R的调节升高,这表明反应更强.
- 在多变量分析中,CXCL9和NPY1R预测了Ki67的减少.
结论:
- CXCL9和NPY1R显示出作为内分泌治疗反应的预测生物标志物的潜力.
- 这些生物标志物可以使ER阳性乳腺癌的个性化治疗策略成为可能.
- 识别不响应者可能会指导添加诸如化疗之类的疗法.
相关概念视频
02:38Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K